Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Centre Georges Francois Leclerc
Age
18–99
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Women
over 18 years
Patient with locally or metastatic advanced breast cancer histologically documented who received at least one chemotherapy regimen that includes an anthracycline and a taxane unless in patients who can not receive these treatments
Patient to be treated with eribulin
Patient that should preventively receive granulocyte growth factors at the first cycle (patient who already experienced febrile neutropenia, patient with a low neutrophil count at baseline, patient with a Performance Status altered or any other condition requiring administration of granulocyte colony stimulating factor as recommended by the oncologist)
For patients of childbearing age, effective contraception during treatment and up to 3 months after stopping treatment
You may not be if
Patient with against-indication to treatment with eribulin such as hypersensitivity to the active substance or to any of the excipients, congenital long QT syndrome
Patient already being treated with eribulin
Patient with clinically detectable brain metastases
Patient with against-indication to treatment with G-CSF such as hypersensitivity to the active substance or to any of the excipients
Pregnant women or nursing
Patient under guardianship or subject to major people protection regime
Patient not affiliated with a social security scheme (beneficiary or beneficiary)
Clareo Health | Evaluation and Modeling of the G-CSF Effect on the Evolution of Neutrophils During Chemotherapy Based on Eribulin
